ALung Launches Hemolung RAS in France at SFAR
Jean-Michel Dutois Hired As French Country Manager
Pittsburgh, PA (September 12, 2013) – ALung Technologies, Inc., a leading developer of innovative respiratory assist devices, today announced its launch of the Hemolung Respiratory Assist System (RAS) in France. ALung will showcase the Hemolung RAS next week at the 2013 National Congress of the French Society of Anesthesia and Intensive Care (SFAR) in Paris. ALung’s entry into the French market is led by Jean-Michel Dutois, a seasoned medical device executive who recently joined ALung as Country Manager for France.
The Hemolung RAS removes carbon dioxide and delivers oxygen directly to the blood, allowing a patient’s lungs to rest and heal in cases of acute respiratory failure. The device received CE Mark approval in February 2013, and is initially being made available to a select group of hospitals participating in ALung’s Hemolung Reference Center Program. “I am very pleased to see this exciting new technology be made available in France,” said Prof. Alain Combes from La Pitié-Salpétrière ICU in Paris, who is participating in the Hemolung Reference Center Program. “In my opinion, there is a lot of promise for extracorporeal lung support devices like the Hemolung RAS to facilitate better outcomes in cases of acute respiratory failure.”
ALung has established a direct sales and support organization in France. “I am very excited to have the opportunity to launch the Hemolung RAS. We have already received tremendous support from local physicians who agree that minimally invasive extracorporeal carbon dioxide removal is an ideal solution for those suffering from respiratory failure,” said Jean-Michel Dutois, ALung’s Country Manager for France. “I look forward to demonstrating the Hemolung RAS and its many benefits at the National Congress of the SFAR.”
The 2013 National Congress of the SFAR will be held from September 18 – 21 at the Palais des Congress de Paris. ALung will showcase the Hemolung RAS at booth number 36.
About the Hemolung RAS
The Hemolung RAS is a dialysis-like alternative or supplement to mechanical ventilation. The system provides Respiratory Dialysis®, a simple, minimally invasive form of extracorporeal carbon dioxide removal (ECCO₂R) and has indications for use in patients with acute respiratory distress syndrome (ARDS) and acute exacerbation of chronic obstructive pulmonary disease (COPD). The device is approved for sale in Europe and Canada.
About ALung Technologies
ALung Technologies, Inc. is a Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation.
For more information, please visit https://www.alung.com.
This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.
Pascale Communications, LLC